| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | AZ-3146 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | 0.023 | 0.6 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.028 | 0.6 |
| mRNA | RO-3306 | GDSC1000 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |